VKH
CLDX icon

Virtu KCG Holdings’s Celldex Therapeutics CLDX Stock Holding History

Virtu KCG Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$291K Buy
7,851
+6,445
+458% +$285K 0.01% 1708
2017
Q1 		$76K Sell
1,406
-8,042
-85% -$419K ﹤0.01% 2753
2016
Q4 		$502K Buy
+9,448
New +$537K 0.01% 1488
2016
Q3 		– Sell
-3,620
Closed -$238K – 3095
2016
Q2 		$238K Buy
3,620
+1,841
+103% +$117K ﹤0.01% 2134
2016
Q1 		$101K Sell
1,779
-225
-11% -$25.3K ﹤0.01% 2328
2015
Q4 		$471K Sell
2,004
-1,184
-37% -$258K 0.01% 1610
2015
Q3 		$504K Buy
3,188
+1,809
+131% +$512K 0.01% 1517
2015
Q2 		$522K Buy
1,379
+595
+76% +$236K 0.01% 1452
2015
Q1 		$328K Sell
784
-952
-55% -$341K 0.01% 1814
2014
Q4 		$475K Sell
1,736
-377
-18% -$93.7K 0.01% 1758
2014
Q3 		$411K Buy
2,113
+1,309
+163% +$285K 0.01% 1919
2014
Q2 		$196K Sell
804
-681
-46% -$154K ﹤0.01% 3088
2014
Q1 		$394K Buy
+1,485
New +$569K ﹤0.01% 2230
2013
Q4 		– Sell
-2,860
Closed -$1.52M – 3817
2013
Q3 		$1.52M Buy
+2,860
New +$981K 0.02% 810

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu KCG Holdings's CLDX Position: Q2 2017 in Review

Virtu KCG Holdings increased its Celldex Therapeutics (CLDX) stake by 458% in Q2 2017, buying an estimated $285K and bringing the position to 7,851 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #1708.

Virtu KCG Holdings first reported a position in CLDX in Q3 2013 and has held it in 14 quarters since. The position peaked at $1.52M in Q3 2013. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Virtu KCG Holdings held 7,851 shares of Celldex Therapeutics worth $291K as of Q2 2017.
  • Virtu KCG Holdings bought 6,445 Celldex Therapeutics shares in Q2 2017, an estimated $285K.
  • Celldex Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1708 holding.
  • Virtu KCG Holdings first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 14 quarters since.
  • Virtu KCG Holdings's Celldex Therapeutics position peaked at $1.52M in Q3 2013.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.